

13 Re PCT/PTO 21 JUN 2001

09/674913
PATENT APPLICATION

1702.401600

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
GUSTAV GAUDERNACK, ET AL.) : Examiner: Unassigned
Int'l Appln. No.: PCT/NO99/00141) : Group Art Unit: Unassigned
Int'l Publn. No.: WO 99/58564) :
U.S. Appln. No.: 09/674,913) :
Nat'l Entry Date: November 8, 2000) :
For: FRAMESHIFT MUTANTS OF) : May 25, 2001
BETA-AMYLOID PRECURSOR) :
PROTEIN AND UBIQUITIN-B) :
AND THEIR USE) :

BOX PCT

Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES
(FORM PCT/DO/EO/920) ("SEQUENCE LISTING NOTIFICATION")

Sir:

In response to the SEQUENCE LISTING NOTIFICATION
mailed March 27, 2001, enclosed please find a computer readable
form and a paper copy of the Sequence Listing under 37 C.F.R.
§ 1.821-1.825, and a Statement Under 37 CFR §1.821(f)
specifying that the Sequence Listing information recorded in
computer readable form on the attached diskette is identical to
the written Sequence Listing.

Although Applicants have responded to the SEQUENCE LISTING NOTIFICATION as noted above, Applicants wish to make the record clear that a computer readable copy and a paper copy of the Sequence Listing under 37 C.F.R. § 1.821-1.825 were filed with the U.S. Patent and Trademark Office on November 8, 2000, on the date of National Entry, together with the application, the National Fee and other items. A copy of the stamped postcard is enclosed as proof of this fact. However, Applicants now recognize that the Sequence Listing that was filed on November 8, 2000 may not be in proper form under the U.S. sequence rules set forth in 37 CFR §§ 1.821-1.825. Accordingly, the computer readable copy and paper copy of the Sequence Listing being submitted herewith have been reformatted in order to place the Sequence Listing in better form under the U.S. sequence rules. By reformatting the Sequence Listing, Applicants submit that no new matter has been added.

Although Applicants believe that no additional fee needs to be filed in connection with this paper, the Commissioner is nonetheless authorized to charge any additional fees or credit any overpayment associated with this paper to Deposit Account No. 06-1205. A duplicate copy of this Response is attached for that purpose.

Applicants' undersigned attorney may be reached in our Washington, D.C. office by telephone at (202) 530-1010. All correspondence should continue to be directed to our address given below.

Respectfully submitted,



Attorney for Applicants

Registration No. 30110

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3801
Facsimile: (212) 218-2200
NMD/llp

1702.401600

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
GUSTAV GAUDERNACK, ET AL.) : Examiner: Unassigned
Int'l Appln. No.: PCT/NO99/00141) : Group Art Unit: Unassigned
Int'l Publn. No.: WO 99/58564) :
U.S. Appln. No.: 09/674,913) :
Nat'l Entry Date: November 8, 2000) :
For: FRAMESHIFT MUTANTS OF) May 25, 2001
BETA-AMYLOID PRECURSOR) :
PROTEIN AND UBIQUITIN-B) :
AND THEIR USE) :

BOX PCT
Commissioner For Patents
Washington, D.C. 20231

STATEMENT UNDER 37 C.F.R § 1.821(f)

Sir:

Applicants hereby submit that the Sequence Listing information recorded in computer readable form on the attached diskette is identical to the paper copy of the Sequence Listing filed concurrently herewith.

Applicants' undersigned attorney may be reached in our Washington, D.C. office by telephone at (202) 530-1010. All correspondence should be directed to our address listed below.

Respectfully submitted,



Registration No. 30110
Attorney for Applicants

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York, 10112-3801
Facsimile: (212) 218-2200

NMD\llp

09574913-052501